Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer

International Journal of Biological Markers

Volumn 20, Issue 2, 2005, Pages 103-111

  Rodriguez J ^a,b   Vazquez J ^a,b   Corte, M D ^a   Lamelas, M ^a,b   Bongera, M ^b   Corte, M G ^a   Alvarez, A ^c   Allende, M ^a,c   Gonzalez, L ^b   Sanchez M ^b   Vijande, M ^a   Garcia Muniz J ^c   Vizoso, F ^a,b  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL DE JOVE   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Breast cancer; Cathepsin D; Prognosis

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; PROTEINASE;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOSOL; DIPLOIDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MOLECULAR WEIGHT; MULTIVARIATE ANALYSIS; ONCOLOGICAL PARAMETERS; PAGET NIPPLE DISEASE; PROBABILITY; PROTEIN CONTENT; SAMPLING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 22944451470     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/jbm.2008.679     Document Type: Article

References (38)

1. Allgayer H, Babic R, Grutzner KU, et al. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 1998; 16: 62-73.
2. Westley BR, May FE. Cathepsin D and breast cancer. Eur J Cancer 1996; 32A: 15-24.
3. Rochefort H, Capony F, Garcia M, et al. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J Cell Biochem 1987; 35: 17-29.
4. Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 1988; 48: 3688-92.
5. Saftig P, Hetman M, Schmahl W, et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 1995; 14: 3599-608.
6. Briozzo P, Badet J, Capony F, et al. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 1991; 194: 252-9.
7. Liaudet E, Derocq D, Rochefort H, Garcia M. Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors. Cell Growth Differ 1995; 6: 1045-52.
8. Remmele W, Sauer-Manthey J. Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Arch A Pathol Anat Histopathol 1993; 422: 467-73.
9. Armas OA, Gerald WL, Lesser ML, Arroyo CD, Norton L, Rosen PP. Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am J Surg Pathol 1994; 18: 158-66.
10. Ravdin PM, Tandon AK, Allred DC, et al. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 1994; 12: 467-74.
11. Tetu B, Brisson J, Cote C, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993; 55: 429-35.
12. Spyratos F, Maudelonde T, Brouillet JP, et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989; 2: 1115-8.
13. Thorpe SM, Rochefort H, Garcia M, et al. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49: 6008-14.
14. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 322: 297-302.
15. Ravdin PM. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 1993; 24: 219-26.
16. Ardavanis A, Gerakini F, Amanatidou A, et al. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance. Anticancer Res 1997; 17: 3665-9.
17. Scorilas A, Yotis J, Pateras C, Trangas T, Talieri M. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 1999; 5: 815-21.
18. Harbeck N, Alt U, Berger U, et al. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int J Biol Markers 2000; 15: 79-83.
19. Dittadi R, Biganzoli E, Boracchi P, et al. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen. Int J Biol Markers 1998; 13: 30-41.
20. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
22. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry 1993; 14: 482-5.
23. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35.
24. Henry JA, McCarthy AL, Angus B, et al. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 1990; 65: 265-71.
25. Nadji M, Fresno M, Nassiri M, Conner G, Herrero A, Morales AR. Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. Hum Pathol 1996; 27: 890-5.
26. O'Donoghue AE, Poller DN, Bell JA, et al. Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat 1995; 33: 137-45.
27. Joensuu H, Toikkanen S, Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 1995; 71: 155-9.
28. Garcia M, Derocq D, Pujol P, Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990; 5: 1809-14.
29. Liaudet E, Garcia M, Rochefort H. Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal. Oncogene 1994; 9: 1145-54.
30. van der Stappen JW, Williams AC, Maciewicz RA, Paraskeva C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996; 67: 547-54.
31. Kobayashi Y, Fukuo Y, Shibuya T, Terashi A. [The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects]. Nippon Ronen Igakkai Zasshi 1990; 27: 578-83.
32. Coopman PJ, Do MT, Thompson EW, Mueller SC. Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. Clin Cancer Res 1998; 4: 507-15.
33. Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metastasis: a protease and a ligand. APMIS 1999; 107: 86-95.
34. Berchem G, Glondu M, Gleizes M, et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 2002; 21: 5951-5.
35. Wolf M, Clark-Lewis I, Buri C, Langen H, Lis M, Mazzucchelli L. Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer. Am J Pathol 2003; 162: 1183-90.
36. Vetvicka V, Vetvickova J, Fusek M. Anti-human procathepsin D activation peptide antibodies inhibit breast cancer development. Breast Cancer Res Treat 1999; 57: 261-9.
37. Vetvicka V, Benes P, Fusek M. Procathepsin D in breast cancer: what do we know? Effects of ribozymes and other inhibitors. Cancer Gene Ther 2002; 9: 854-63.
38. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M. How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 2003; 10: 261-6.